Susquehanna International Group’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.3M | Buy |
+230,731
| New | +$8.63M | ﹤0.01% | 3225 |
|
|
2025
Q4 | – | Sell |
-86,924
| Closed | -$6.83M | – | 12512 |
|
|
2025
Q3 | $7.22M | Sell |
86,924
-8,287
| -9% | -$600K | ﹤0.01% | 3509 |
|
|
2025
Q2 | $6.99M | Sell |
95,211
-24,019
| -20% | -$1.74M | ﹤0.01% | 3376 |
|
|
2025
Q1 | $13.6M | Buy |
119,230
+82,496
| +225% | +$5.02M | ﹤0.01% | 2153 |
|
|
2024
Q4 | $1.85M | Buy |
+36,734
| New | +$1.92M | ﹤0.01% | 5497 |
|
|
2024
Q3 | – | Sell |
-6,454
| Closed | -$229K | – | 12111 |
|
|
2024
Q2 | $210K | Sell |
6,454
-27,363
| -81% | -$750K | ﹤0.01% | 10256 |
|
|
2024
Q1 | $852K | Buy |
33,817
+1,482
| +5% | +$35K | ﹤0.01% | 7264 |
|
|
2023
Q4 | $1.05M | Sell |
32,335
-87,169
| -73% | -$2.39M | ﹤0.01% | 6880 |
|
|
2023
Q3 | $3.26M | Buy |
119,504
+51,718
| +76% | +$1.5M | ﹤0.01% | 4239 |
|
|
2023
Q2 | $1.51M | Buy |
67,786
+16,093
| +31% | +$370K | ﹤0.01% | 5760 |
|
|
2023
Q1 | $1.12M | Buy |
51,693
+39,356
| +319% | +$863K | ﹤0.01% | 6519 |
|
|
2022
Q4 | $251K | Sell |
12,337
-28,850
| -70% | -$723K | ﹤0.01% | 9545 |
|
|
2022
Q3 | $1.06M | Buy |
41,187
+30,754
| +295% | +$823K | ﹤0.01% | 6505 |
|
|
2022
Q2 | $248K | Sell |
10,433
-40,418
| -79% | -$881K | ﹤0.01% | 10081 |
|
|
2022
Q1 | $1.15M | Sell |
50,851
-9,906
| -16% | -$211K | ﹤0.01% | 6785 |
|
|
2021
Q4 | $1.2M | Buy |
+60,757
| New | +$1.23M | ﹤0.01% | 6791 |
|
|
2021
Q3 | – | Sell |
-28,780
| Closed | -$602K | – | 12811 |
|
|
2021
Q2 | $633K | Buy |
28,780
+15,195
| +112% | +$338K | ﹤0.01% | 8989 |
|
|
2021
Q1 | $323K | Sell |
13,585
-42,776
| -76% | -$1.14M | ﹤0.01% | 10447 |
|
|
2020
Q4 | $1.47M | Buy |
56,361
+45,673
| +427% | +$962K | ﹤0.01% | 5781 |
|
|
2020
Q3 | $186K | Buy |
+10,688
| New | +$170K | ﹤0.01% | 9511 |
|
|
2020
Q2 | – | Sell |
-26,675
| Closed | -$375K | – | 10201 |
|
|
2020
Q1 | $317K | Buy |
+26,675
| New | +$330K | ﹤0.01% | 7870 |
|
|
2019
Q4 | – | Sell |
-49,259
| Closed | -$686K | – | 9807 |
|
|
2019
Q3 | $696K | Buy |
49,259
+12,777
| +35% | +$157K | ﹤0.01% | 6537 |
|
|
2019
Q2 | $407K | Buy |
36,482
+18,602
| +104% | +$207K | ﹤0.01% | 7697 |
|
|
2019
Q1 | $210K | Sell |
17,880
-53,002
| -75% | -$659K | ﹤0.01% | 7805 |
|
|
2018
Q4 | $947K | Buy |
+70,882
| New | +$937K | ﹤0.01% | 4784 |
|
|
2018
Q3 | – | Sell |
-25,670
| Closed | -$359K | – | 9315 |
|
|
2018
Q2 | $404K | Buy |
+25,670
| New | +$447K | ﹤0.01% | 7231 |
|
|
2017
Q4 | – | Sell |
-67,778
| Closed | -$1.23M | – | 9308 |
|
|
2017
Q3 | $1.31M | Sell |
67,778
-62,979
| -48% | -$939K | ﹤0.01% | 4751 |
|
|
2017
Q2 | $1.54M | Buy |
130,757
+8,957
| +7% | +$97.4K | ﹤0.01% | 4379 |
|
|
2017
Q1 | $1.33M | Sell |
121,800
-82,315
| -40% | -$723K | ﹤0.01% | 4520 |
|
|
2016
Q4 | $1.48M | Buy |
204,115
+193,001
| +1,737% | +$1.51M | ﹤0.01% | 4692 |
|
|
2016
Q3 | $72K | Sell |
11,114
-43,234
| -80% | -$251K | ﹤0.01% | 8040 |
|
|
2016
Q2 | $297K | Buy |
+54,348
| New | +$283K | ﹤0.01% | 6969 |
|
|
2015
Q4 | – | Sell |
-23,626
| Closed | -$107K | – | 9470 |
|
|
2015
Q3 | $89K | Sell |
23,626
-86,428
| -79% | -$439K | ﹤0.01% | 9190 |
|
|
2015
Q2 | $661K | Buy |
110,054
+76,300
| +226% | +$468K | ﹤0.01% | 7072 |
|
|
2015
Q1 | $189K | Buy |
33,754
+21,228
| +169% | +$76.8K | ﹤0.01% | 8670 |
|
|
2014
Q4 | $38K | Sell |
12,526
-5,156
| -29% | -$15.7K | ﹤0.01% | 9410 |
|
|
2014
Q3 | $47K | Sell |
17,682
-25,696
| -59% | -$68K | ﹤0.01% | 9230 |
|
|
2014
Q2 | $122K | Buy |
43,378
+4,298
| +11% | +$12.7K | ﹤0.01% | 9347 |
|
|
2014
Q1 | $170K | Buy |
39,080
+25,407
| +186% | +$88.8K | ﹤0.01% | 8344 |
|
|
2013
Q4 | $44K | Buy |
+13,673
| New | +$27.6K | ﹤0.01% | 8821 |
|
Other funds holding CORT
ISL
VPM
VCM
PA
Susquehanna International Group's CORT Position: Q1 2026 in Review
Susquehanna International Group opened a new position in Corcept Therapeutics (CORT) in Q1 2026: 230,731 shares worth $9.3M. The stake represents ﹤0.01% of the portfolio and ranks #3225 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in CORT as recently as Q3 2025.
Susquehanna International Group first reported a position in CORT in Q4 2013 and has held it in 40 quarters since. The position peaked at $13.6M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.
- Susquehanna International Group held 230,731 shares of Corcept Therapeutics worth $9.3M as of Q1 2026.
- Corcept Therapeutics was a new Susquehanna International Group position in Q1 2026.
- Corcept Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3225 holding.
- Susquehanna International Group first reported a position in Corcept Therapeutics in Q4 2013 and has held it in 40 quarters since.
- Susquehanna International Group's Corcept Therapeutics position peaked at $13.6M in Q1 2025.
- 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.